Press releases
- Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
- Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
- Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
- Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
More ▼
Key statistics
On Monday, Neurocrine Biosciences Inc (NBIX:DEU) closed at 132.55, -2.57% below its 52-week high of 136.05, set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 131.55 |
---|---|
High | 132.55 |
Low | 129.65 |
Bid | 131.45 |
Offer | 131.70 |
Previous close | 130.05 |
Average volume | 194.78 |
---|---|
Shares outstanding | 100.64m |
Free float | 99.36m |
P/E (TTM) | 38.94 |
Market cap | 14.26bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 15 minutes, as of May 06 2024.
More ▼